Clinical Trial Information Request for Protocol 16-232 Title A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti CD20 x anti CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death 1 monoclonal antibody, in Patients with B cell Malignancies PI Site Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study. Name Email Phone